Results 71 to 80 of about 36,129 (239)
Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell +6 more
wiley +1 more source
Abstract Objectives The identification of novel noninvasive diagnostic and prognostic biomarkers for pediatric inflammatory bowel disease (PIBD), including pediatric Crohn's disease (pCD) and ulcerative colitis (pUC), is crucial for improving therapeutic outcomes.
Tereza Pinkasova +11 more
wiley +1 more source
Abstract Objective We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very‐early onset inflammatory bowel disease (VEO‐IBD). Methods A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepatology and Nutrition ...
Luca Scarallo +45 more
wiley +1 more source
Purpose To report the clinical outcomes of adalimumab in treating refractory Behcet’s disease (BD)-related uveitis in paediatric or adolescent patients. Methods Retrospective review of five paediatric or adolescent patients with BD-related uveitis with a
Mary Ho +7 more
doaj +1 more source
Abstract Objective Paediatric inflammatory bowel disease (IBD) surgery is delivered across heterogeneous settings, with limited paediatric‐specific evidence guiding organisation of care, perioperative management, and operative strategy. We characterised contemporary international practice.
Vojtech Dotlacil +24 more
wiley +1 more source
Background: Few studies have evaluated the effectiveness of adalimumab in the real-life setting in psoriatic arthritis (PsA).Objective: To evaluate the 2-year retention rate of adalimumab in PsA patients.
Salvatore D'Angelo +33 more
doaj +1 more source
The ImproveCareNow Registry: Prediction of different remission rates in pediatric ulcerative colitis
Abstract Objectives Identifying predictors of clinical remission in pediatric ulcerative colitis (UC) will impact the therapeutic approach. We aimed to predict time to first (TFR), corticosteroid‐free (TCSFR, ≥3 months corticosteroid withdrawal), and sustained remission (TSR, ≥6 months).
Jonathan Van Hecke +7 more
wiley +1 more source
Human immunodeficiency virus infection mimicking very early onset inflammatory bowel disease
Abstract Very early onset inflammatory bowel disease (VEO‐IBD), defined as diagnosis before 6 years of age, is often associated with immune dysregulation and monogenic etiologies; however, infectious mimics may be overlooked in low‐prevalence regions. We report a 4‐year‐old male with poor weight gain, intermittent diarrhea, elevated fecal calprotectin,
Rasha Abi Radi Abou Jaoudeh +2 more
wiley +1 more source
Background: Pyoderma gangrenosum (PG) is a rare inflammatory cutaneous disorder that frequently occurs in association with systemic diseases such as inflammatory bowel disease (IBD).
Fotios S. Fousekis +7 more
doaj +1 more source
ABSTRACT Paradoxical atopic dermatitis (AD) can arise during biologic therapy for psoriasis due to an immune‐axis imbalance. We describe a 47‐year‐old man who developed severe AD while receiving secukinumab, which was successfully managed with the addition of dupilumab, allowing long‐term control of both diseases.
So Yun Park +6 more
wiley +1 more source

